IgA腎症治療の現在の臨床試験の状況
Jackson Kim1, Fahmeedah Kamal1, Richard Lafayette1
1Department of Nephrology, Stanford Hospital, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abstract:
IgA nephropathy is in a transformative era, with disease-targeted therapies advancing beyond supportive care. This Trial Watch summarizes recent clinical progress in complement inhibition, endothelin receptor antagonism, and B cell and plasma-cell-directed strategies, highlighting promising reductions in proteinuria, preservation of renal function, and the emerging framework for precision, biomarker-guided treatment.
関連する概念動画
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care


